Skip to main content

Advertisement

SpringerLink
Log in

Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016

  • Review
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a spectrum of liver pathologies characterized by hepatic steatosis with a history of little to no alcohol consumption or secondary causes of hepatic steatosis. The prevalence of NAFLD is 20–25 % of the general population in the Western countries and is associated with metabolic risk factors such as obesity, diabetes mellitus, and dyslipidemia. The spectrum of disease ranges from simple steatosis to nonalcoholic steatohepatitis, fibrosis, and cirrhosis. Advanced fibrosis is the most significant predictor of mortality in NAFLD. It is crucial to assess for the presence and degree of hepatic fibrosis in order to make therapeutic decisions and predict clinical outcomes. Liver biopsy, the current gold standard to assess the liver fibrosis, has a number of drawbacks such as invasiveness, sampling error, cost, and inter-/intra-observer variability. There are currently available a number of noninvasive tests as an alternative to liver biopsy for fibrosis staging. These noninvasive fibrosis tests are increasingly used to rule out advanced fibrosis and help guide disease management. While these noninvasive tests perform relatively well for ruling out advanced fibrosis, they also have limitations. Understanding the strengths and limitations of liver biopsy and the noninvasive tests is necessary for deciding when to use the appropriate tests in the evaluation of patients with NAFLD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology. 2002;123:1705–1725.

    Article  PubMed  Google Scholar 

  2. Craft S. Insulin resistance syndrome and Alzheimer disease: pathophysiologic mechanisms and therapeutic implications. Alzheimer Dis Assoc Disord. 2006;20:298–301.

    Article  CAS  PubMed  Google Scholar 

  3. Monteiro R, Azevedo I. Chronic inflammation in obesity and the metabolic syndrome. Mediators Inflamm. 2010. doi:10.1155/2010/289645.

    PubMed  PubMed Central  Google Scholar 

  4. Afdhal NH. Management of nonalcoholic fatty liver disease: a 60-year-old man with probable nonalcoholic fatty liver disease: weight reduction, liver biopsy, or both? JAMA. 2012;308:608–616.

    Article  CAS  PubMed  Google Scholar 

  5. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37:917–923.

    Article  PubMed  Google Scholar 

  6. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013;10:686–690.

    Article  CAS  PubMed  Google Scholar 

  7. Ogden C, Carroll M, Kit B, Flegal K. Prevalence of obesity and trends in body mass index among US children and adolescents, 1999–2010. JAMA. 2012;307:483–490.

    Article  PubMed  Google Scholar 

  8. Fatty NN, Disease L, Mulhall BP, et al. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221–1231.

    Article  Google Scholar 

  9. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10:330–344.

    Article  CAS  PubMed  Google Scholar 

  10. Chalasani N, Younossi Z, Lavine J. The diagnosis and management of nonalcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005–2023.

    Article  PubMed  Google Scholar 

  11. Sheth SG, Gordon FD, Chopra S. Nonalcoholic steatohepatitis. Ann Intern Med. 1997;126:137–145.

    Article  CAS  PubMed  Google Scholar 

  12. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387–1395.

    Article  PubMed  Google Scholar 

  13. Ekstedt M, Hagström H, Nasr P, Fredrikson M, Stål P, Kechagias S, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61:1547–1554.

    Article  CAS  PubMed  Google Scholar 

  14. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467–2474.

    Article  CAS  PubMed  Google Scholar 

  15. Nalbantoglu I, Brunt EM. Role of liver biopsy in nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20:9026–9037.

    PubMed  PubMed Central  Google Scholar 

  16. Afdhal NH, Nunes D. Evaluation of liver fibrosis: a concise review. Am J Gastroenterol. 2004;99:1160–1174.

    Article  PubMed  Google Scholar 

  17. Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005;128:1898–1906.

    Article  PubMed  Google Scholar 

  18. Manning DS, Afdhal NH. Diagnosis and quantitation of fibrosis. Gastroenterology. 2008;134:1670–1681.

    Article  CAS  PubMed  Google Scholar 

  19. Kelleher TB, Afdhal N. Noninvasive assessment of liver fibrosis. Clin Liver Dis. 2005;9:667–683.

    Article  PubMed  Google Scholar 

  20. McPherson S, Stewart SF, Henderson E, Burt AD, Day CP. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with nonalcoholic fatty liver disease. Gut. 2010;59:1265–1269.

    Article  PubMed  Google Scholar 

  21. Sheth SG, Flamm SL, Gordon FD, Chopra S. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol. 1998;93:44–48.

    Article  CAS  PubMed  Google Scholar 

  22. Ohgo H, Yokoyama H, Hirose H, et al. Significance of ALT/AST ratio for specifying subjects with metabolic syndrome in its silent stage. Diabetes Metab Syndr Clin Res Rev. 2009;3:3–6.

    Article  Google Scholar 

  23. Sorbi D, Boynton J, Lindor KD. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol. 1999;94:1018–1022.

    Article  CAS  PubMed  Google Scholar 

  24. Ruffillo G, Fassio E, Alvarez E, et al. Comparison of NAFLD fibrosis score and BARD score in predicting fibrosis in nonalcoholic fatty liver disease. J Hepatol. 2011;54:160–163.

    Article  PubMed  Google Scholar 

  25. Lee TH, Han SH, Yang JD, Kim D, Ahmed M. Prediction of advanced fibrosis in nonalcoholic fatty liver disease: an enhanced model of BARD score. Gut Liver. 2013;7:323–328.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Rodrigues S, Rodrigues-Pinto E, Albuquerque A, et al. Significant correlation between liver stiffness, liver histology, and APRI score. Am J Gastroenterol. 2012. doi:10.1038/ajg.2012.271.

    Google Scholar 

  27. Pissaia A, Borderie D, Bernard D, Scatton O, Calmus Y, Conti F. APRI and FIB-4 scores are useful after liver transplantation independently of etiology. Transplant Proc. 2009;41:679–681.

    Article  PubMed  Google Scholar 

  28. Tapper EB, Krajewski K, Lai M, et al. Simple non-invasive biomarkers of advanced fibrosis in the evaluation of nonalcoholic fatty liver disease. Gastroenterol Rep. 2014;2:276–280.

    Article  Google Scholar 

  29. Angulo P, Bugianesi E, Bjornsson ES, et al. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2013. doi:10.1053/j.gastro.2013.06.057.

    PubMed  PubMed Central  Google Scholar 

  30. Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut. 2008;57:1441–1447.

    Article  CAS  PubMed  Google Scholar 

  31. Cichoż-Lach H, Celiński K, Prozorow-Król B, Swatek J, Słomka M, Lach T. The BARD score and the NAFLD fibrosis score in the assessment of advanced liver fibrosis in nonalcoholic fatty liver disease. Med Sci Monit. 2012;18:CR735–CR740.

    PubMed  PubMed Central  Google Scholar 

  32. Ratziu V, Giral P, Charlotte F, et al. Liver fibrosis in overweight patients. Gastroenterology. 2000;118:1117–1123.

    Article  CAS  PubMed  Google Scholar 

  33. Syn WK, Choi SS, Diehl AM. Apoptosis and cytokines in nonalcoholic steatohepatitis. Clin Liver Dis. 2009;13:565–580.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Diab DL, Yerian L, Schauer P, et al. Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients. Clin Gastroenterol Hepatol. 2008;6:1249–1254.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology. 2009;50:1072–1078.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Cusi K, Chang Z, Harrison S, et al. Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with nonalcoholic fatty liver disease. J Hepatol. 2014;60:167–174.

    Article  CAS  PubMed  Google Scholar 

  37. Pimentel CMG, Jiang Z, Otsubo T, Feldbrügge L, Challies T, Nasser I, et al. Poor inter-test reliability between CK18 kits as a biomarker of NASH. Dig Dis Sci. 2016;61:905–912.

    Article  CAS  PubMed  Google Scholar 

  38. Friedrich-Rust M, Rosenberg W, Parkes J, Herrmann E, Zeuzem S, Sarrazin C. Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis. BMC Gastroenterol. 2010;10:103.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Guha IN, Parkes J, Roderick P, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European liver fibrosis panel and exploring simple markers. Hepatology. 2008;47:455–460.

    Article  PubMed  Google Scholar 

  40. Parkes J, Guha IN, Roderick P, et al. Enhanced Liver Fibrosis (ELF) test accurately identifies liver fibrosis in patients with chronic hepatitis C. J Viral Hepat. 2011;18:23–31.

    Article  CAS  PubMed  Google Scholar 

  41. Parkes J, Roderick P, Harris S, et al. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut. 2010;59:1245–1251.

    Article  CAS  PubMed  Google Scholar 

  42. Sumida Y, Yoneda M, Hyogo H, et al. Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population. BMC Gastroenterol. 2012;12:2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Adler M, Gulbis B, Moreno C, et al. The predictive value of FIB-4 versus FibroTest, APRI, FibroIndex and Forns index to noninvasively estimate fibrosis in hepatitis C and nonhepatitis C liver diseases. Hepatology. 2008;47:762–763.

    Article  PubMed  Google Scholar 

  44. Lassailly G, Caiazzo R, Hollebecque A, et al. Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity. Eur J Gastroenterol Hepatol. 2011;23:499–506.

    Article  PubMed  Google Scholar 

  45. Ratziu V, Giral P, Munteanu M, et al. Screening for liver disease using non-invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia. Aliment Pharmacol Ther. 2007;25:207–218.

    Article  CAS  PubMed  Google Scholar 

  46. Oh S, Afdhal NH. Hepatic fibrosis: are any of the serum markers useful? Curr Gastroenterol Rep. 2001;3:12–18.

    Article  CAS  PubMed  Google Scholar 

  47. Ratziu V, Massard J, Charlotte F, et al. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with nonalcoholic fatty liver disease. BMC Gastroenterol. 2006;6:6.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Leroy V, Sturm N, Faure P, et al. Prospective evaluation of FibroTest®, FibroMeter®, and HepaScore® for staging liver fibrosis in chronic hepatitis B: comparison with hepatitis C. J Hepatol. 2014;61:28–34.

    Article  PubMed  Google Scholar 

  49. Calès P, Boursier J, Oberti F, et al. FibroMeters: a family of blood tests for liver fibrosis. Gastroenterol Clin Biol. 2008;32:40–51.

    Article  PubMed  Google Scholar 

  50. Becker L, Salameh W, Sferruzza A, et al. Validation of Hepascore, compared to simple indices of fibrosis, in US patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol. 2009;7:696–701.

    Article  PubMed  Google Scholar 

  51. Bonder A, Tapper EB, Afdhal NH. Contemporary assessment of hepatic fibrosis. Clin Liver Dis. 2015;19:123–134.

    Article  PubMed  Google Scholar 

  52. Suzuki A, Angulo P, Lymp J, Li D, Satomura S, Lindor K. Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with nonalcoholic fatty liver disease. Liver Int. 2005;25:779–786.

    Article  CAS  PubMed  Google Scholar 

  53. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45:846–854.

    Article  CAS  PubMed  Google Scholar 

  54. Tanwar S, Trembling PM, Guha IN, et al. Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease. Hepatology. 2013;57:103–111.

    Article  CAS  PubMed  Google Scholar 

  55. Lee SS, Park SH, Kim HJ, et al. Non-invasive assessment of hepatic steatosis: prospective comparison of the accuracy of imaging examinations. J Hepatol. 2010;52:579–585.

    Article  CAS  PubMed  Google Scholar 

  56. van Werven JR, Marsman HA, Nederveen AJ, et al. Assessment of hepatic steatosis in patients undergoing liver resection: comparison of US, CT, T1-weighted dual-echo MR imaging, and point-resolved 1H MR spectroscopy. Radiology. 2010;256:159–168.

    Article  PubMed  Google Scholar 

  57. Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002;123:745–750.

    Article  PubMed  Google Scholar 

  58. Saverymuttu SH, Joseph AE, Maxwell JD. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J (Clin Res Ed). 1986;292:13–15.

    Article  CAS  Google Scholar 

  59. Hepburn MJ, Vos JA, Fillman EP, Lawitz EJ. The accuracy of the report of hepatic steatosis on ultrasonography in patients infected with hepatitis C in a clinical setting: a retrospective observational study. BMC Gastroenterol. 2005;5:14.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Rofsky NM, Fleishaker H. CT and MRI of diffuse liver disease. Semin Ultrasound CT MR. 1995;16:16–33.

    Article  CAS  PubMed  Google Scholar 

  61. Borra RJH, Salo S, Dean K, et al. Nonalcoholic fatty liver disease: rapid evaluation of liver fat content with in-phase and out-of-phase MR imaging. Radiology. 2009;250:130–136.

    Article  PubMed  Google Scholar 

  62. Kim D, Kim WR, Talwalkar JA, Kim HJ, Ehman RL. Advanced fibrosis in nonalcoholic fatty liver disease: noninvasive assessment with MR elastography. Radiology. 2013;268:411–419.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Singh S, Venkatesh SK, Wang Z, et al. Diagnostic performance of magnetic resonance elastography in staging liver fibrosis: a systematic review and meta-analysis of individual participant data. Clin Gastroenterol Hepatol. 2015;13:440–451.e6.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Huwart L, Sempoux C, Vicaut E, et al. Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology. 2008;135:32–40.

    Article  PubMed  Google Scholar 

  65. http://www.accessdata.fda.gov/cdrh_docs/pdf12/K123806.pdf (cited 2015 Aug 30).

  66. Wong VWS, Vergniol J, Wong GLH, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology. 2010;51:454–462.

    Article  CAS  PubMed  Google Scholar 

  67. Nobili V, Vizzutti F, Arena U, et al. Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. Hepatology. 2008;48:442–448.

    Article  CAS  PubMed  Google Scholar 

  68. Bonder A, Afdhal N. Utilization of FibroScan in clinical practice. Curr Gastroenterol Rep. 2014;16:1–7.

    Article  Google Scholar 

  69. Tapper EB, Castera L, Afdhal NH. FibroScan (vibration-controlled transient elastography): where does it stand in the United States practice. Clin Gastroenterol Hepatol. 2014. doi:10.1016/j.cgh.2014.04.039.

    Google Scholar 

  70. Cassinotto C, Lapuyade B, Mouries A, et al. Non-invasive assessment of liver fibrosis with impulse elastography: comparison of supersonic shear imaging with ARFI and FibroScan®. J Hepatol. 2014;61:550–557.

    Article  PubMed  Google Scholar 

  71. Coco B, Oliveri F, Maina AM, et al. Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases. J Viral Hepat. 2007;14:360–369.

    Article  CAS  PubMed  Google Scholar 

  72. Kim KM, Choi WB, Park SH, et al. Diagnosis of hepatic steatosis and fibrosis by transient elastography in asymptomatic healthy individuals: a prospective study of living related potential liver donors. J Gastroenterol. 2007;42:382–388.

    Article  PubMed  Google Scholar 

  73. Castéra L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128:343–350.

    Article  PubMed  Google Scholar 

  74. Mueller S, Millonig G, Sarovska L, et al. Increased liver stiffness in alcoholic liver disease: differentiating fibrosis from steatohepatitis. World J Gastroenterol. 2010;16:966–972.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Pais R, Lupşor M, Poantă L, et al. Liver biopsy versus noninvasive methods—fibroscan and fibrotest in the diagnosis of nonalcoholic fatty liver disease: a review of the literature. Rom J Intern Med. 2009;47:331–340.

    PubMed  Google Scholar 

  76. Myers RP, Pomier-Layrargues G, Kirsch R, et al. Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology. 2012;55:199–208.

    Article  PubMed  Google Scholar 

  77. Nahon P, Kettaneh A, Tengher-Barna I, et al. Assessment of liver fibrosis using transient elastography in patients with alcoholic liver disease. J Hepatol. 2008;49:1062–1068.

    Article  PubMed  Google Scholar 

  78. Fraquelli M, Rigamonti C, Casazza G, et al. Etiology-related determinants of liver stiffness values in chronic viral hepatitis B or C. J Hepatol. 2011;54:621–628.

    Article  PubMed  Google Scholar 

  79. Arena U, Vizzutti F, Corti G, et al. Acute viral hepatitis increases liver stiffness values measured by transient elastography. Hepatology. 2008;47:380–384.

    Article  CAS  PubMed  Google Scholar 

  80. Wong VWS, Vergniol J, Wong GLH, et al. Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. Am J Gastroenterol. 2012;107:1862–1871.

    Article  PubMed  Google Scholar 

  81. Millonig G, Reimann FM, Friedrich S, et al. Extrahepatic cholestasis increases liver stiffness (fibroScan) irrespective of fibrosis. Hepatology. 2008;48:1718–1723.

    Article  PubMed  Google Scholar 

  82. Millonig G, Friedrich S, Adolf S, et al. Liver stiffness is directly influenced by central venous pressure. J Hepatol. 2010;52:206–210.

    Article  PubMed  Google Scholar 

  83. Goertz RS, Egger C, Neurath MF, Strobel D. Impact of food intake, ultrasound transducer, breathing maneuvers and body position on acoustic radiation force impulse (ARFI) elastometry of the liver. Ultraschall Med. 2012;33:380–385.

    Article  CAS  PubMed  Google Scholar 

  84. Tsochatzis EA, Gurusamy KS, Ntaoula S, Cholongitas E, Davidson BR, Burroughs AK. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. J Hepatol. 2015;54:650–659.

    Article  Google Scholar 

  85. Crespo G, Fernández-Varo G, Mariño Z, et al. ARFI, FibroScan®, ELF, and their combinations in the assessment of liver fibrosis: a prospective study. J Hepatol. 2012;57:281–287.

    Article  PubMed  Google Scholar 

  86. Rotman Y, Koh C, Zmuda JM, Kleiner DE, Liang TJ. The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology. 2010;52:894–903.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Valenti L, Al-Serri A, Daly AK, et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology. 2010;51:1209–1217.

    Article  CAS  PubMed  Google Scholar 

  88. Dongiovanni P, Romeo S, Valenti L. Genetic factors in the pathogenesis of nonalcoholic fatty liver and steatohepatitis. Biomed Res Int. 2015;2015:460190.

    Article  PubMed  PubMed Central  Google Scholar 

  89. Liu Y-L, Patman GL, Leathart JBS, et al. Carriage of the PNPLA3 rs738409 C>G polymorphism confers an increased risk of nonalcoholic fatty liver disease associated hepatocellular carcinoma. J Hepatol. 2015;61:75–81.

    Article  CAS  Google Scholar 

  90. Liu Y-L, Reeves HL, Burt AD, et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with nonalcoholic fatty liver disease. Nat Commun. 2014. doi:10.1038/ncomms5309.

    Google Scholar 

  91. Sookoian S, Castaño GO, Scian R, et al. Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity. Hepatology. 2015;61:515–525.

    Article  CAS  PubMed  Google Scholar 

  92. Calès P, Lainé F, Boursier J, et al. Comparison of blood tests for liver fibrosis specific or not to NAFLD. J Hepatol. 2009;50:165–173.

    Article  PubMed  Google Scholar 

  93. Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7:1104–1112.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: An inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and FibroTest. Hepatology. 2007;46:32–36.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Liver Center, Department of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center and Harvard Medical School, 110 Francis St #8e, Boston, MA, 0221, USA

    Dharmesh H. Kaswala, Michelle Lai & Nezam H. Afdhal

Authors
  1. Dharmesh H. Kaswala
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michelle Lai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nezam H. Afdhal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nezam H. Afdhal.

Ethics declarations

Conflict of interest

Dharmesh Kaswala MD: None. Michelle Lai MD: None. Nezam H Afdhal MD: Consultant: EchoSens, Sandhill Scientific, Chief Medical Officer, Spring Bank Pharmaceuticals

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kaswala, D.H., Lai, M. & Afdhal, N.H. Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016. Dig Dis Sci 61, 1356–1364 (2016). https://doi.org/10.1007/s10620-016-4079-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-016-4079-4

Keywords

Search

Navigation